PCOS NASH Liraglutide

• Research type

  Research Study

• Full title

  Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Liraglutide?

• IRAS ID

  33598

• Contact name

  Stephen L Atkin

• Eudract number

  2009-015927-94

• ISRCTN Number

  n/a

• Research summary

  Title Are markers of heart disease in women with Polycystic Ovary Syndrome and Nonalcoholic Steatohepatitis increased compared to each condition alone, and can these markers be improved with Liraglutide? Why is this important? Polycystic Ovary Syndrome (PCOS) is a common condition affecting women of reproductive age and these women are more likely to suffer from fatty liver disease, including Nonalcoholic Steatohepatitis (NASH) an inflamed fatty liver. Women with either of these conditions have an increased risk of heart disease, but the effect of both PCOS and NASH on markers of heart disease is unknown. It is important to know this as detection and treatment at an early stage could reduce heart disease. Liraglutide is an injection treatment used in diabetes but its effect in either PCOS or NASH have not been examined. Often after cessation of weight loss medication the weight returns to near the pre treatment level. Metformin has been shown to maintain weight loss after cessation of the weight loss drug Rimonabant and this study will also examine if Metformin is as effective after Liraglutide therapy. This study will examine the markers of heart disease and the effect of Liraglutide; knowledge learned from this will hopefully improve the management of each condition.

• REC name

  Yorkshire & The Humber - Leeds East Research Ethics Committee

• REC reference

  09/H1306/120

• Date of REC Opinion

  8 Feb 2010

• REC opinion

  Further Information Favourable Opinion